80,597 Shares in CVS Health Co. (NYSE:CVS) Purchased by One68 Global Capital LLC

One68 Global Capital LLC purchased a new stake in shares of CVS Health Co. (NYSE:CVS) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 80,597 shares of the pharmacy operator’s stock, valued at approximately $3,618,000. CVS Health comprises about 1.9% of One68 Global Capital LLC’s portfolio, making the stock its 13th biggest holding.

Other large investors have also recently made changes to their positions in the company. Principal Financial Group Inc. grew its position in CVS Health by 4.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator’s stock worth $90,200,000 after purchasing an additional 66,244 shares during the period. Hall Laurie J Trustee grew its holdings in shares of CVS Health by 25,484.4% in the fourth quarter. Hall Laurie J Trustee now owns 11,513 shares of the pharmacy operator’s stock worth $517,000 after acquiring an additional 11,468 shares during the period. B&D White Capital Company LLC purchased a new stake in CVS Health during the fourth quarter valued at $417,000. Watts Gwilliam & Co. LLC lifted its holdings in CVS Health by 9.8% in the fourth quarter. Watts Gwilliam & Co. LLC now owns 7,302 shares of the pharmacy operator’s stock valued at $334,000 after acquiring an additional 650 shares during the period. Finally, Seizert Capital Partners LLC boosted its position in CVS Health by 22.8% in the fourth quarter. Seizert Capital Partners LLC now owns 569,527 shares of the pharmacy operator’s stock worth $25,566,000 after purchasing an additional 105,708 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on CVS shares. JPMorgan Chase & Co. raised their price objective on shares of CVS Health from $80.00 to $81.00 and gave the stock an “overweight” rating in a report on Tuesday, February 18th. Evercore ISI upped their price objective on CVS Health from $60.00 to $65.00 and gave the stock an “outperform” rating in a research note on Monday, January 27th. Robert W. Baird raised their target price on shares of CVS Health from $51.00 to $71.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 15th. Piper Sandler upped their price target on shares of CVS Health from $72.00 to $74.00 and gave the stock an “overweight” rating in a research report on Friday, March 21st. Finally, Barclays lifted their target price on shares of CVS Health from $71.00 to $73.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $71.83.

Insider Activity at CVS Health

In other news, Director Michael F. Mahoney purchased 30,000 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was bought at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the acquisition, the director now directly owns 39,356 shares of the company’s stock, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP James David Clark sold 7,513 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares in the company, valued at $556,941.90. This represents a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.22% of the stock is currently owned by corporate insiders.

CVS Health Price Performance

Shares of NYSE CVS opened at $65.00 on Wednesday. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. The business’s fifty day moving average price is $66.45 and its two-hundred day moving average price is $58.74. The firm has a market capitalization of $81.95 billion, a PE ratio of 17.76, a P/E/G ratio of 0.98 and a beta of 0.57. CVS Health Co. has a 1-year low of $43.56 and a 1-year high of $71.45.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. On average, research analysts expect that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be issued a dividend of $0.665 per share. The ex-dividend date is Tuesday, April 22nd. This represents a $2.66 annualized dividend and a dividend yield of 4.09%. CVS Health’s payout ratio is 72.68%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.